Innovus Pharma Announces U.S. Food and Drug Administration Clearance of its GlucoGorx™ Glucose Monitoring Device Test Kit
April 12, 2018
SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared the Company’s GlucoGorx™ Glucose Monitoring Test Kit that includes a glucose meter,
Recent related news
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients with Small Cell Lung Cancer and Grants Priority Review
PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #BristolMyers--U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab)
13 hours ago • Business Wire
NEW YORK CITY (dpa-AFX) - Today's Daily Dose brings you news about FDA clearance of Innovus' GlucoGorx Glucose Monitoring Test Kit; Nymox securing equity...
6 days ago • FinanzNachrichten.de
RUTHERFORD, N.J., April 16, 2018 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular...
3 days ago • GlobeNewswire